Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

First-in-Class Selective Nurr1:RXRα Modulators with a Unique Biophysical Mechanism driving multi-pathway Disease Modification in Parkinson’s Disease.

Objective

NURRAPEUTICS develops first-in-class, selective Nurr1:RXRα small-molecule modulators that act through a unique biophysical mechanism driving multi-pathway neuroprotection, anti-inflammatory activity, and proteostasis restoration. Nurr1 is a well-established regulator of neuronal survival and homeostasis, and current Parkinson’s treatments remain purely symptomatic with no impact on progression. By selectively modulating Nurr1—rather than broadly activating RXR—our compounds unlock a differentiated, mechanism-based approach to multi-pathway disease modification in Parkinson’s disease.
Using a proprietary Mechanism–Structure–Function approach, SyNoesis has generated a portfolio of brain-penetrant, orally active candidate modulators supported by orthogonal biophysical assays and robust in-vivo efficacy across multiple PD models. These candidates show favorable profiling in potency, selectivity, ADMET and preliminary safety. Two new composition-of-matter patent families covering the Gen-3/4 chemotypes are fully drafted and ready for filing upon project invitation for funding.
During the 24-month EIC Pre-Accelerator, NURRAPEUTICS will progress from TRL 4 to TRL 6, completing CMC development, PK/PD integration, and two-species GLP toxicology to produce a Quality-Assurance-approved IMPD/CTA dossier. This will enable a Phase-I-ready asset within 12 months post-project. In parallel, we will reach IRL 8 by finalizing the business plan, investor data room and partnering strategy.
The outcome of NURRAPEUTICS is a first-in-class, mechanism-driven therapeutic approach with strong preclinical evidence for disease-modifying potential in Parkinson’s disease, developed through a capital-efficient EU pathway and positioned for Accelerator Fast-Track readiness.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-WIDERA-2025-02

See all projects funded under this call

Coordinator

SYNOESIS THERAPEUTICS LTD
Net EU contribution
€ 492 450,00
Address
77 STROVOLOU STREET
2018 NICOSIA
Cyprus
SME
Yes
Region
Κύπρος Κύπρος Κύπρος
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data